Galectin Therapeutics

Galectin Therapeutics is a biotechnology company focused on developing novel therapies for patients suffering from chronic liver and skin diseases, as well as cancer. Their primary focus is on non-alcoholic steatohepatitis (NASH) cirrhosis, a serious liver disease with no current cure other than liver transplantation. They are developing a carbohydrate-based drug called belapectin that inhibits the galectin-3 protein, which is implicated in many inflammatory, fibrotic, and malignant diseases.

Beyond NASH cirrhosis, Galectin Therapeutics is also pursuing therapies for severe atopic dermatitis, moderate-to-severe plaque psoriasis, and exploring the use of belapectin in combination immunotherapy for advanced melanoma and other cancers. Their approach leverages extensive scientific and development expertise, aiming to create cost-effective and efficient treatments with a focus on diseases with serious, life-threatening consequences for patients.

Galectin Therapeutics is a biotechnology company committed to developing innovative therapies for patients suffering from chronic liver and skin diseases, as well as cancer. They focus on utilizing their expertise in galectin science and drug development to create new treatments targeting galectin proteins, which play a crucial role in various inflammatory, fibrotic, and malignant conditions. By leveraging their unique carbohydrate technology and extensive scientific resources, Galectin Therapeutics strives to provide effective and safe treatment options for patients facing serious and often life-threatening diseases with limited current therapies.

Galectin Therapeutics emphasizes a collaborative and results-oriented culture. The company values innovation and scientific excellence, fostering a supportive environment where employees can contribute their expertise and work together to develop life-changing therapies for patients with chronic liver diseases and cancer.